SCHEMBL15628126

SCHEMBL15628126

N[C@H]1CN(c2cccc(Cl)c2)c2ccccc2NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.40
CHRM1 P11229 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 3/20 0.38
MAPT P10636 3/20 0.38
ALOX5 P09917 2/20 0.38
ALDH1A1 P00352 3/20 0.38
FADS1 O60427 1/20 0.38
KDM4E B2RXH2 1/20 0.37
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
HSD11B1 P28845 1/20 0.37
LMNA P02545 1/20 0.37
ALOX12 P18054 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DRD2 P14416 1/20 0.36
DRD3 P35462 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15628122 0.87 MEN1 (0.40) HTR7CHRM1MEN1KMT2AGAA
SCHEMBL7657174 0.86 GAA (0.42) CHRM1MEN1KMT2AGAAMAPT
SCHEMBL20580064 0.86 GAA (0.42) CHRM1MEN1KMT2AGAAMAPT
SCHEMBL7657163 0.86 GAA (0.42) CHRM1MEN1KMT2AGAAMAPT
Bromide SCHEMBL6178391 0.85 GAA (0.41) CHRM1MEN1KMT2AGAAMAPT
SCHEMBL15628123 0.84 HTR6 (0.45) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL15628098 0.84 MEN1 (0.38) MEN1KMT2AGAAMAPTALOX5
SCHEMBL15628083 0.80 KCNH2 (0.38) MEN1KMT2AGAAMAPTALOX5
SCHEMBL20580338 0.80 ALDH1A1 (0.37) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL20580336 0.80 ALDH1A1 (0.37) MEN1KMT2AGAAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2897944-B1 SUBSTITUTED 1,5-BENZODIAZEPINONE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2016-10-26 EP disclosed
US-9187434-B2 Substituted 1,5-benzodiazepinones compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-17 US disclosed
US-20150274679-A1 SUBSTITUTED 1,5-BENZODIAZEPINONES COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2015-10-01 US disclosed
WO-2014047369-A1 SUBSTITUTED 1,5-BENZODIAZEPINONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274679-A1 SUBSTITUTED 1,5-BENZODIAZEPINONES COMPOUNDS CNR1, RXFP3, NPY1R HTR7 77/4885CHRM1 175/4885MEN1 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.